AbbVie Overview
- Status
-
Public
- Employees
-
57,000
- Stock Symbol
-
ABBV
- Investments
-
45
- Share Price
-
$295.03
- (As of Friday Closing)
AbbVie General Information
Description
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio, while the 2026 acquisition of Apogee adds to AbbVie's immunology depth.
Contact Information
Website
www.abbvie.comCorporate Office
- 1 North Waukegan Road
- North Chicago, IL 60064
- United States
Corporate Office
- 1 North Waukegan Road
- North Chicago, IL 60064
- United States
AbbVie Timeline
AbbVie Stock Performance
As of 13-Nov-2026, AbbVie’s stock price is $295.03. Its current market cap is $521B with 1.77B shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $295.03 | $294.45 | $190.75 - $302.93 | $521B | 1.77B | 4.79M | $5.82 |
AbbVie Financials Summary
As of 30-Sep-2026, AbbVie has a trailing 12-month revenue of $66B.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 526,560,211 | 466,944,715 | 377,853,835 | 321,096,334 |
| Revenue | 66,014,000 | 61,160,000 | 56,334,000 | 54,318,000 |
| EBITDA | 23,160,000 | 17,363,000 | 14,262,000 | 16,632,000 |
| Net Income | 10,342,000 | 4,226,000 | 4,278,000 | 4,863,000 |
| Total Assets | 147,680,000 | 133,960,000 | 135,161,000 | 134,711,000 |
| Total Debt | 80,903,000 | 67,496,000 | 67,144,000 | 59,385,000 |
AbbVie Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
AbbVie Comparisons
Industry
Financing
Details
AbbVie Competitors (32)
One of AbbVie’s 32 competitors is Biogen, a Formerly VC-backed company based in Cambridge, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Biogen | Formerly VC-backed | Cambridge, MA | ||||
| Gilead | Formerly VC-backed | Foster City, CA | ||||
| Lilly USA | Corporation | Indianapolis, IN | ||||
| Amgen | Formerly PE-Backed | Thousand Oaks, CA | ||||
| Roche | Corporation | Basel, Switzerland |
AbbVie Patents
AbbVie Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026226780-A1 | Anti-nectin-4 conditional il-15 immuno-cytokines | Pending | 23-Apr-2025 | ||
| US-20260306664-A1 | Prophylactic steroid regimen for recombinant adeno-associated viral vector therapies | Pending | 03-Apr-2025 | ||
| WO-2026213546-A1 | Prophylactic steroid regimen for recombinant adeno-associated viral vector therapies | Pending | 03-Apr-2025 | ||
| WO-2026210399-A1 | Amylin agonist for use in a method of treating obesity | Pending | 01-Apr-2025 | ||
| JP-2026159374-A | Triple-specific binding protein | Pending | 20-Mar-2025 | C07K16/2851 |
AbbVie Signals
AbbVie Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
AbbVie Investments & Acquisitions (45)
AbbVie’s most recent deal was a Corporate Asset Purchase with Nxera Pharma (NXE0033744 in United Kingdom) for . The deal was made on 04-Nov-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Nxera Pharma (NXE0033744 in United Kingdom) | 04-Nov-2026 | Corporate Asset Purchase | Buildings and Property | ||
| ADARx Pharmaceuticals | 01-Oct-2026 | PIPE | Drug Discovery | ||
| Apogee Therapeutics | 03-Sep-2026 | Merger/Acquisition | Biotechnology | ||
| West Pharmaceutical Services (Device Manufacturing Facility in Tempe, Arizona) | 01-Jul-2026 | Corporate Asset Purchase | Buildings and Property | ||
| Kestrel Therapeutics | 28-Apr-2026 | Merger/Acquisition | Drug Discovery |
AbbVie ESG
Risk Overview
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Pharmaceuticals
Subindustry
Rank
Percentile
AbbVie Exits (6)
AbbVie’s most recent exit was on 09-Jun-2021 from Kojin TX. The exit was categorized as with 11 buyers.
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Kojin TX | 09-Jun-2021 | Completed |
|
||
| Lyndra Therapeutics | 11-Feb-2019 | Completed |
|
||
| BioArctic | 20-Sep-2016 | Completed |
|
||
| Reata Pharmaceuticals | 26-May-2016 | Completed |
|
||
| MIMETAS | 22-Dec-2015 | Grant | Completed |
|
AbbVie Affiliates
Subsidiaries (8)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Apogee Therapeutics | Waltham, MA | 2022 | |
| DJS Antibodies | Bicester, United Kingdom | 2014 | |
| Abbott - AbbVie Multiple Employer Pension Plan | Abbott Park City, IL | 2013 | |
| AbbVie (Women's Drug Portfolio) | Dublin, Ireland | 2012 | |
| iSTAR Medical | Wavre, Belgium | 2010 |
AbbVie FAQs
-
Where is AbbVie headquartered?
AbbVie is headquartered in North Chicago, IL.
-
What is the size of AbbVie?
AbbVie has 57,000 total employees.
-
What industry is AbbVie in?
AbbVie’s primary industry is Drug Discovery.
-
Is AbbVie a private or public company?
AbbVie is a Public company.
-
What is AbbVie’s stock symbol?
The ticker symbol for AbbVie is ABBV.
-
What is the current stock price of AbbVie?
As of 13-Nov-2026 the stock price of AbbVie is $295.03.
-
What is the current market cap of AbbVie?
The current market capitalization of AbbVie is $521B.
-
What is AbbVie’s current revenue?
The trailing twelve month revenue for AbbVie is $66B.
-
Who are AbbVie’s competitors?
Biogen, Gilead, Lilly USA, Amgen, and Roche are some of the 32 competitors of AbbVie.
-
What is AbbVie’s annual earnings per share (EPS)?
AbbVie’s EPS for 12 months was $5.82.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process